Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Acute Leukemia · Myeloid Leukemia · Acute Myelogenous Leukemia · Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Myelogenous Leukemia · Myelogenous Leukemia, Acute · Myelogenous Leukemia in Relapse · Transplant-Related Disorder · Allogeneic Disease · Refractory AML
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 306 (planned)
- Started
- Jan 2026
- Main results expected
- Feb 2029
- Fully finished
- Feb 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS) -Phase 3
Measured over: Up to 5 years post-randomization
Complete Remission (CR) at Day 28 Post-HSCT - Phase 2
Measured over: Day 28 post-HSCT
Incidence of Grade ≥4 Non-Hematologic Toxicity
Measured over: Up to 6 months post-HSCT
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07157514 · record last updated 2025-09-10 · checked 2026-11-09 15:47 UTC